UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: A modeling study
Expanding access to MDMA-AT to patients with chronic and severe PTSD will provide substantial health and financial benefits.
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective, while delivering substantial clinical benefit.